Researchers at the National Cancer Institute (NCI) have developed a dendritic cell vaccine for treating multiple cancer types. The NCI seeks licensing and/or co-development research collaborations to bring this invention to the public.
The invention is a novel methodology for predicting a mantle cell lymphoma (MCL) cancer patient’s survival prognosis. This information is important in helping determine the best course of treatment for the patient.
Researchers at the National Cancer Institute (NCI) developed a DNA vaccine using conserved elements of HIV-1 Gag, administered in a prime-boost vaccination protocol. Two of the HIV Gag CE DNA vectors have been tested in a rhesus macaque model. Priming with the Gag CE vaccine and boosting with full length Gag DNA showed increased immune responses when compared to vaccination with Gag alone. Researchers seek licensing and/or co-development research collaborations for development this DNA vaccine.
The National Cancer Institute seeks partners to license or co-develop an FDA/EMA-approved Chemistry, Manufacturing and Controls (CMC) large-scale manufacturing process for the production of GMP-grade chimeric antibodies.
Researchers at the National Cancer Institute’s Biopharmaceutical Development Program recently developed massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines and oncolytic immunotherapies, for which the NCI seeks licensees or co-development collaborations.
Researchers at the National Institute on Drug Abuse (NIDA) seek licensing and/or co-development research collaborations to further develop, evaluate or commercialize the software, Mobile Personalized Assessment & Learning for Addiction Treatment and Behavioral Modification. NIDA researchers developed this software for use in treating substance use disorders (drugs, alcohol, smoking) that provides personalized feedback to users.
NCI scientists developed a method that uses urine samples to detect early-stage cancers and that could supplement low-dose computed tomography (LD-CT) to significantly decrease its expensive false negative/false positive results, and the NCI seeks co-developers or licensees to commercialize this technology.
This technology provides improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the improved processes relate to improved processes for producing viral DNA template.
Researchers at the National Cancer Institute (NCI) have developed a novel method enabling rapid, GMP-compliant manufacture of retroviral vectors encoding anti-tumor T cell receptors (TCRs). T cells engineered through the use of these vectors to express tumor-reactive TCRs will be useful in adoptive cell immunotherapy for the treatment of cancer. Researchers at the NCI seek licensing and/or co-development research collaborations for this invention.
This invention identifies two polymorphic genetic markers in the SLCO1B3 (formerly SLC21A8) gene, called 334T>G and 699G>A, that can be measured in genomic DNA obtained from a blood sample to predict survival from diagnosis of prostate cancer in that individual patient.
Novel thalidomide analogs and their use as immunomodulatory agents are disclosed in this invention by scientists at the National Institute on Aging (NIA). These therapeutic compounds could reduce chronic systemic and central nervous system inflammation. The NIA seeks licensing or co-development partners to commercialize this technology.
The National Institutes of Health, through The National Institutes of Health - Clinical Center (NIH-CC) and the National Heart Lung and Blood Institute (NHLBI), seeks licensing and/or co-development partners for a nitric oxide cream for the treatment of ulcers associated with sickle cell disease.